# RanluspecTM EU Approval for Retinal Disease Treatment

> Lupin's biosimilar RanluspecTM launches across Europe for retinal disease treatment after EU approval.
- Title: RanluspecTM EU Approval for Retinal Disease Treatment
- Summary: Lupin's biosimilar RanluspecTM launches across Europe for retinal disease treatment after EU approval.
- Keywords: ranluspectm, eu approval, lupin ltd, sandoz, retinal disease treatment, biosimilar, ranibizumab, The Economic Times
- Source: The Economic Times — https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/lupin-partner-sandoz-launches-ranluspectm-across-europe-for-retinal-disease-treatment/articleshow/135758397.cms
- Published: 2026-11-12T06:51:00+00:00
- Read time: 1 min
- Topics: ranluspectm, eu approval, lupin ltd, sandoz, retinal disease treatment, biosimilar, ranibizumab
## EU Approval for RanluspecTM
Lupin's commercial partner Sandoz receives EU Commission approval for RanluspecTM biosimilar of Ranibizumab.

> The launch of Ranluspec in Europe advances Lupin’s strategy of bringing high-quality biosimilars to more patients suffering from retinal and choroidal vascular diseases
## RanluspecTM Treatment Indications
RanluspecTM treats neovascular age-related macular degeneration, macular edema, diabetic macular edema, proliferative diabetic retinopathy, and choroidal neovascularization.

> Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds and inhibits vascular endothelial growth factor A
## RanluspecTM Launch Across Europe
Lupin and Sandoz launch RanluspecTM across Europe excluding Germany for retinal disease treatment.

> Together with Sandoz, we will expand access to this important treatment across the region
## Key takeaway

Lupin and Sandoz launch RanluspecTM, a biosimilar of Ranibizumab, across Europe for retinal diseases after European Commission approval.